Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis

Keishi Oda, Hiroshi Ishimoto, Sohsuke Yamada, Hisako Kushima, Hiroshi Ishii, Tomotoshi Imanaga, Tatsuhiko Harada, Yuji Ishimatsu, Nobuhiro Matsumoto, Keisuke Naito, Kazuhiro Yatera, Masamitsu Nakazato, Jun-Ichi Kadota, Kentaro Watanabe, Shigeru Kohno, Hiroshi Mukae, Keishi Oda, Hiroshi Ishimoto, Sohsuke Yamada, Hisako Kushima, Hiroshi Ishii, Tomotoshi Imanaga, Tatsuhiko Harada, Yuji Ishimatsu, Nobuhiro Matsumoto, Keisuke Naito, Kazuhiro Yatera, Masamitsu Nakazato, Jun-Ichi Kadota, Kentaro Watanabe, Shigeru Kohno, Hiroshi Mukae

Abstract

Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with high mortality. However, few studies have so far reviewed analyses of autopsy findings in patients with AE-IPF.

Methods: We retrospectively reviewed 52 consecutive patients with AE-IPF who underwent autopsies at five university hospitals and one municipal hospital between 1999 and 2013. The following variables were abstracted from the medical records: demographic and clinical data, autopsy findings and complications during the clinical course until death.

Results: The median age at autopsy was 71 years (range 47-86 years), and the subjects included 38 (73.1%) males. High-dose corticosteroid therapy was initiated in 45 (86.5%) patients after AE-IPF. The underling fibrotic lesion was classified as having the usual interstitial pneumonia (UIP) pattern in all cases. Furthermore, 41 (78.8%) patients had diffuse alveolar damage (DAD), 15 (28.8%) exhibited pulmonary hemorrhage, nine (17.3%) developed pulmonary thromboembolism and six (11.5%) were diagnosed with lung carcinoma. In addition, six (11.5%) patients developed pneumothorax prior to death and 26 (53.1%) developed diabetes that required insulin treatment after the administration of high-dose corticosteroid therapy. In addition, 15 (28.8%) patients presented with bronchopneumonia during their clinical course and/or until death, including fungal (seven, 13.5%), cytomegalovirus (six, 11.5%) and bacterial (five, 9.6%) infections.

Conclusions: The pathological findings in patients with AE-IPF represent not only DAD, but also a variety of pathological conditions. Therefore, making a diagnosis of AE-IPF is often difficult, and the use of cautious diagnostic approaches is required for appropriate treatment.

Figures

Figure 1
Figure 1
A 78-year-old male with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). High resolution computed tomography (HRCT) images at the initial diagnosis of IPF showed subpleural-predominant interstitial fibrosis, traction bronchiectasis (arrow) and honeycombing (arrowhead) (A). HRCT images at the onset of acute exacerbation (12 months after the initial diagnosis) showed diffuse areas of ground glass attenuations superimposed on underlying fibrotic opacities (B). The underling fibrotic lesions were classified as the UIP pattern, including dense interstitial fibrosis with focal squamous or bronchial metaplasia (inset), alternating with only bland-looking alveolar walls (H&E, ×100) (C). DAD with hyaline membranes (inset) superimposed on a background fibrotic and edematous lung with several fibroblastic foci (H&E, ×100) (D).
Figure 2
Figure 2
The histopathological findings of the lung specimens obtained at autopsy. The microscopic findings of the lung showed diffuse alveolar hemorrhage (arrows) without any specific evidence of vasculitis (A) or pulmonary thromboembolism (B) (H&E, ×10). The macroscopic findings of the heart showed overt right ventricular hypertrophy, confirmed by an increased (≥5 mm) right ventricular wall thickness (double-headed arrows) (C). Immunohistochemical staining of an inflamed lung tissue specimen revealed a number of specific cytomegalovirus-positive cells (proliferating type II pneumocytes) (D).
Figure 3
Figure 3
A flow diagram showing the pathological findings of the patients with AE-IPF. *One patient showed pulmonary thromboembolism with alveolar hemorrhage.

References

    1. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203. doi: 10.1164/ajrccm.157.1.9704130.
    1. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Paine R, Flint A, Lynch JP, Martinez FJ. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002;19:275–283. doi: 10.1183/09031936.02.00182002.
    1. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213–2217. doi: 10.1164/ajrccm.162.6.2003049.
    1. Rudd RM, Prescott RJ, Chalmers JC, Johnston ID, Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society British Thoracic Society Study on cryptogenic fibrosing alveolitis: Response to treatment and survival. Thorax. 2007;62:62–66. doi: 10.1136/thx.2005.045591.
    1. Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, Sakamoto K, Johkoh T, Nishimura M, Ono K, Kitaichi M. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:103–110.
    1. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI.
    1. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993;103:1808–1812. doi: 10.1378/chest.103.6.1808.
    1. Society AT, Society ER. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. doi: 10.1164/ajrccm.165.2.ats01.
    1. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–643. doi: 10.1164/rccm.200703-463PP.
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL.
    1. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27:143–150. doi: 10.1183/09031936.06.00114004.
    1. Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J. 2003;22:821–826. doi: 10.1183/09031936.03.00022703.
    1. Churg A, Müller NL, Silva CI, Wright JL. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol. 2007;31:277–284. doi: 10.1097/01.pas.0000213341.70852.9d.
    1. Parambil JG, Myers JL, Ryu JH. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest. 2005;128:3310–3315. doi: 10.1378/chest.128.5.3310.
    1. Katzenstein AL, Bloor CM, Leibow AA. Diffuse alveolar damage–the role of oxygen, shock, and related factors. A review. Am J Pathol. 1976;85:209–228.
    1. Sulavik SB. The concept of “organizing pneumonia”. Chest. 1989;96:967–969. doi: 10.1378/chest.96.5.967.
    1. Forman MB, Wilson BH, Sheller JR, Kopelman HA, Vaughn WK, Virmani R, Friesinger GC. Right ventricular hypertrophy is an important determinant of right ventricular infarction complicating acute inferior left ventricular infarction. J Am Coll Cardiol. 1987;10:1180–1187. doi: 10.1016/S0735-1097(87)80116-X.
    1. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128:2393–2399. doi: 10.1378/chest.128.4.2393.
    1. Sawabe M, Saito M, Naka M, Kasahara I, Saito Y, Arai T, Hamamatsu A, Shirasawa T. Standard organ weights among elderly Japanese who died in hospital, including 50 centenarians. Pathol Int. 2006;56:315–323. doi: 10.1111/j.1440-1827.2006.01966.x.
    1. Husari A, Beydoun A, Sheik Ammar A, Maakaron JE, Taher A. The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. J Thromb Thrombolysis. 2013;35:81–82. doi: 10.1007/s11239-012-0784-9.
    1. Perri D, Cole DE, Friedman O, Piliotis E, Mintz S, Adhikari NK. Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. Eur Respir J. 2007;30:1014–1017. doi: 10.1183/09031936.00026107.
    1. Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum. 2007;56:2065–2071. doi: 10.1002/art.22633.
    1. Sakamoto K, Taniguchi H, Kondoh Y, Wakai K, Kimura T, Kataoka K, Hashimoto N, Nishiyama O, Hasegawa Y. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106:436–442. doi: 10.1016/j.rmed.2011.11.006.
    1. Sprunger DB, Olson AL, Huie TJ, Fernandez-Perez ER, Fischer A, Solomon JJ, Brown KK, Swigris JJ. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–132. doi: 10.1183/09031936.00041411.
    1. Patel SR, Karmpaliotis D, Ayas NT, Mark EJ, Wain J, Thompson BT, Malhotra A. The role of open-lung biopsy in ARDS. Chest. 2004;125:197–202. doi: 10.1378/chest.125.1.197.
    1. Esteban A, Fernández-Segoviano P, Frutos-Vivar F, Aramburu JA, Nájera L, Ferguson ND, Alía I, Gordo F, Ríos F. Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern Med. 2004;141:440–445. doi: 10.7326/0003-4819-141-6-200409210-00009.
    1. Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002;126:1064–1070.
    1. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994;330:377–381. doi: 10.1056/NEJM199402103300601.
    1. Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153:1089–1093. doi: 10.1093/aje/153.11.1089.
    1. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–752. doi: 10.1378/chest.129.3.746.
    1. Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40:93–100. doi: 10.1183/09031936.00115511.
    1. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047. doi: 10.1164/rccm.200404-571OC.
    1. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–1482. doi: 10.1378/chest.128.3.1475.
    1. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3:285–292. doi: 10.1513/pats.200601-005TK.
    1. Inase N, Sawada M, Ohtani Y, Miyake S, Isogai S, Sakashita H, Miyazaki Y, Yoshizawa Y. Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. Intern Med. 2003;42:565–570. doi: 10.2169/internalmedicine.42.565.
    1. Sakamoto S, Homma S, Miyamoto A, Kurosaki A, Fujii T, Yoshimura K. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49:109–115. doi: 10.2169/internalmedicine.49.2359.
    1. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954–963. doi: 10.1093/clinids/11.6.954.
    1. Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180:167–175. doi: 10.1164/rccm.200810-1596OC.
    1. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, IPFnet investigators Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73. doi: 10.1186/1465-9921-14-73.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner